Ascelia Pharma Q1'25: FDA submission ahead - ABG
Detta är en aktieanalys producerad av tredje part och reflekterar därför nödvändigtvis ej våra åsikter och värderingar
Orviglance FDA submission during the summer
Good cost control
Conf call at 10:00 CEST
Recent relevant events
In mid'March '25, Ascelia communicated a positive outcome of the pre-NDA meeting with the FDA. In mid'April, Ascelia finished the warrants TO 1 capital raise, raising gross proceeds of SEK 43m. On 7 May, Ascelia held its AGM in Malmö, adopting all resolutions on the agenda. All board members including the chairman of the board were re-elected. Earlier this week, Ascelia's CEO Magnus Corfitzen held a presentation at the ABG Investor days and Ascelia clinical collaborators presented SPARKLE data at the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Annual Meeting.
Good cost control
Conf call at 10:00 CEST
Recent relevant events
In mid'March '25, Ascelia communicated a positive outcome of the pre-NDA meeting with the FDA. In mid'April, Ascelia finished the warrants TO 1 capital raise, raising gross proceeds of SEK 43m. On 7 May, Ascelia held its AGM in Malmö, adopting all resolutions on the agenda. All board members including the chairman of the board were re-elected. Earlier this week, Ascelia's CEO Magnus Corfitzen held a presentation at the ABG Investor days and Ascelia clinical collaborators presented SPARKLE data at the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Annual Meeting.